UBM India announces the premier edition of CPhI’s ‘Response to 483s’ in Mumbai
A workshop to address the serious challenges incurred by the issuance of 483s
Mumbai, 28th July 2017: CPhI Conferences, a division of UBM India, which hosts a number of successful pharmaceutical conferences announced the premier edition of ‘Response to 483s’ Workshop scheduled on 21st August 2017 at The Westin Garden City, Mumbai.
The importance of compliance cannot be undermined in preventing unethical conduct and violations of the law. Many a times, failure to comply can lead to issuance of Form 483 and warning letters, which have an impact on reputation, new drug approvals, competitor response, loss of business and requires immense management intervention. By devising a well thought out corrective action plan, companies can mitigate the risk of further regulatory action.
read complete press release @ click here
Disclaimer: Goevnts is the Media Partner to the event
Related Posts:
- CPhI conferences announces the 2nd Annual Biosimilars Congress India
- The Second Energy Internet and “the Belt &Road” Forum 2017
- Call for Papers “Energy Storage Innovations USA” November 15 – 16, 2017 | Santa Clara, CA, USA
- UBM’s 2nd Annual Biosimilars Congress India is set on Aug 8-9 2017 in Hyderabad
- POWER WEEK 13 – 17 November 2017, Singapore